Results 41 to 50 of about 15,790 (257)

Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative [PDF]

World Journal of Gastrointestinal Oncology, 2020
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis can be performed in two ways: Open or closed abdominal technique.To evaluate the impact of HIPEC method on post-operative and long-term survival outcomes.Patients undergoing CRS with HIPEC from 2000-2017 were identified in the United States ...
Leiting, Jennifer L, Cloyd, Jordan M, Ahmed, Ahmed, Fournier, Keith, Lee, Andrew J, Dessureault, Sophie, Felder, Seth, Veerapong, Jula, Baumgartner, Joel M, Clarke, Callisia, Mogal, Harveshp, Staley, Charles A, Zaidi, Mohammad Y, Patel, Sameer H, Ahmad, Syed A, Hendrix, Ryan J, Lambert, Laura, Abbott, Daniel E, Pokrzywa, Courtney, Raoof, Mustafa, LaRocca, Christopher J, Johnston, Fabian M, Greer, Jonathan, Grotz, Travis E   +23 more
openaire   +4 more sources

Simulating drug penetration during hyperthermic intraperitoneal chemotherapy

Drug Delivery, 2021
Hyperthermic intraperitoneal chemotherapy (HIPEC) is administered to treat residual microscopic disease after debulking cytoreductive surgery. During HIPEC, a limited number of catheters are used to administer and drain fluid containing chemotherapy (41 ...
Daan R. Löke, Roxan F. C. P. A. Helderman, Nicolaas A. P. Franken, Arlene L. Oei, Pieter J. Tanis, Johannes Crezee, H. Petra Kok   +6 more
doaj   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

La chimiohyperthermie intrapéritonéale (CHIP) dans les cancers ovariens [PDF]

, 2014
RésuméLe cancer de l’ovaire reste, en France, la quatrième cause de décès par cancer chez la femme. Il s’agit d’une maladie souvent diagnostiquée à un stade évolué avec carcinose péritonéale (CP) et dont l’histoire naturelle est marquée par des récidives
Bakrin, N., Chene, G., Classe, J.-M., Glehen, O., Gouy, S., Pomel, C.   +5 more
core   +1 more source

A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy

Frontiers in Oncology, 2021
Background: To identify the maximum tolerated dose (MTD) of hyperthermic intraperitoneal cisplatin at 43°C among gynecological cancer patients.Methods: In this Phase I dose-finding trial, Bayesian optimal interval (BOIN) design was used.
Chui-ying Chan, Hui Li, Miao-fang Wu, Chang-hao Liu, Huai-wu Lu, Zhong-qiu Lin, Jing Li   +6 more
doaj   +1 more source

Aerosolization of nanotherapeutics as a newly emerging treatment regimen for peritoneal carcinomatosis

, 2019
Recent advances in locoregional chemotherapy have opened the door to new approaches for the clinical management of peritoneal carcinomatosis (PC) by facilitating the delivery of anti-neoplastic agents directly to the tumor site, while mitigating adverse ...
Ceelen, Wim, De Smedt, Stefaan, Remaut, Katrien, Shariati, Molood, Willaert, Wouter   +4 more
core   +1 more source

Peritoneal carcinosis of ovarian origin [PDF]

, 2010
Epithelial ovarian cancer (EOC) is the second most common genital malignancy in women and is the most lethal gynecological malignancy, with an estimated five-year survival rate of 39%.
Fagotti, A, Fanfani, F, Gallotta, V, Naldini, A, ROMANO, Federico, Rossitto, C, Scambia, G., Vigliotta, M   +7 more
core   +2 more sources

Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion [PDF]

, 2013
BackgroundTo evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) as an adjuvant chemotherapy in advanced gastric cancer (AGC) patients with serosal invasion.MethodsPatients who received radical surgery and palliative surgery between January 2002 ...
Chang, Bo-Min, Chen, I-Shu, Chen, Yu-Chia, Chou, Nan-Hua, Kang, Lung-Yun, Liu, Shiuh-Inn, Mok, King-Tong, Tsai, Cheng-Chong, Wang, Being-Whey   +8 more
core   +2 more sources

Cytoreduction with hyperthermic intra peritoneal and intra thoracic chemotherapy for metastatic Sertoli-Leydig cell tumor of the ovary

Gynecologic Oncology Reports, 2020
Sertoli Leydig cell tumor (SLCT) is a rare sex-cord stromal tumor of the ovary that generally has a benign course. Here, we report an unusual case of recurrent, metastatic SLCT and its unique management with a combination of cytoreductive surgery ...
Nicholas K. Larsen, Matthew J. Reilly, Seunghyug Kwon, Brian W. Loggie, Marcus W. Balters   +4 more
doaj  

Hyperthermic intraperitoneal chemotherapy: Rationale and technique

World Journal of Gastrointestinal Oncology, 2010
The combination of complete cytoreductive surgery and perioperative intraperitoneal chemotherapy provides the only chance for long-term survival for selected patients diagnosed with a variety of peritoneal neoplasms, either primary or secondary to digestive or gynecologic malignancy.
Gloria Ortega-Pérez, L. Gonzalez-Bayon, Santiago González-Moreno   +2 more
openaire   +3 more sources